The Kidney Function Tests Market is expected to register a CAGR of 5.62% during the forecast period, 2022-2027.
Kidney function tests are simple procedures that often use blood or urine to help diagnose problems within the kidneys. COVID-19 has also affected patients' kidney function. According to a study "Association of Proteinuria and Hematuria with Acute Kidney Injury and Mortality in Hospitalized Patients with COVID-19" published in November 2020, more than 40% of admitted patients with COVID-19 showed symptoms of abnormal kidney function, such as albuminuria or hematuria. The market is projected to grow during the violence due to increased screening of patients with corona worldwide. Furthermore, according to a study published in medRXiv in April 2020, in adult patients, COVID-19 urinary incontinence was commonly found in patients with moderate to severe disease. In children, exposure to the urinary tract COVID-19 has been reported among those who suffer from a mild form of COVID-19. Urinary tract infections COVID-19 were detected from day 1 to day 52 after the onset of the disease.
Some of the factors driving the growth of the market include an increase in chronic kidney disease, an increase in awareness about diagnostic methods for kidney function, and technological advances in diagnostic equipment and tools.
According to a study "HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis" published in January 2021, the estimated number of people with diabetes worldwide, and 20 times higher than the number of people living with HIV / AIDS worldwide. Therefore, kidney disease is one of the most common diseases in the world, which is expected to boost market growth as this will increase the need for kidney function tests to control the disease.
In addition, diabetes and high blood pressure are considered major factors in the growing burden of chronic kidney disease worldwide. According to the International Diabetes Atlas tenth Edition 2021, 537 million adults (20-79 years) are living with diabetes, approximately1 in 10. This number is predicted to rise to 643 million by 2030 and 783 million by 2045. Over 3 in 4 adults with diabetes live in low- and middle-income countries.
Additionally, market players embrace a variety of strategies such as product launch, development, collaboration, acquisition, integration, and expansion to maximize market share. For example, in August 2020, RenalytixAI received approval from the Unitd States Food and Drug Administration (FDA) for its new KidneyIntelX test. AI-enabled clinical trials designed to identify and improve clinical management of patients with Type 2 diabetes with rapid progressive kidney disease. The emergence of highly technologically advanced products is expected to further market growth in the forecast period.
However, the high cost of diagnostic procedures and strict regulations are expected to hamper market growth in the near future.
Dipstick is a type of plastic stick that has a chemical line on it in the form of lines. Dipstick is dipped in urine, and when the color of the ribbon changes, it indicates the presence of abnormal substances such as protein, blood, redness, bacteria, and sugar. This helps to identify a range of kidney and urinary problems such as chronic kidney disease, bladder diseases, and kidney stones.
Report published by National Kidney Foundation Inc. in March 2020 stated that hospitalized people with COVID-19 were at higher risk of serious kidney injury (AKI), which could lead to serious illness and even death. A similar study found that patients with COVID-19, who were hospitalized between March 11 and April 26, 2020, were twice as likely to develop AKI compared to non-COVID patients who developed AKI simultaneously in 2019, which was calculated. 56.9% compared to 25.1%, respectively. In August 2021, ID Genomics (IDG), a Seattle-based company, has invented a dipstick-based, for simultaneous identification for large number of genetic variants of SARS-CoV2 and received a grant of USD 300,000 from National Institute of Health (NIH).
In addition, according to the above source, most patients with serious COVID-19 (AKI) complications are still working on the lower kidneys after recovery. According to the study "Using dipstick urinalysis to predict the development of kidney damage in patients with COVID-19" published in February 2022, the levels of proteinuria and hematuria in dipstick urine analysis can be used to predict AKI and renal replacement therapy (RRT ) in hospitalized patients. by COVID-19.Therefore, an increase in the incidence of kidney failure and chronic kidney failure due to COVID is expected to promote partial growth during the forecast period due to ease of diagnosis and availability.
Globally, rising government efforts to address and treat kidney disease are at the forefront of the dipstick test. In addition, the increase in the number of adults and the growing investment in the field of kidney function testing is driving partial growth. For example, in January 2020, Sweden's Elypta AB collected a USD 7.0 million fund for a urine cancer screening test. Additionally, in February 2019, Healthy.io raised USD 18 million for home urine testing in a Series B sponsorship led by Aleph, with the participation of Samsung Followers and individual investors. Therefore, because of the above factors, the segment may witness growth during the forecast period.
Some of the factors driving the growth of the market in the North American region include better health care infrastructure, an increase in urinary tract infections, and more widely available diagnostic tests.
The impact of coronavirus was significant in the region, especially in the North America. The Johns Hopkins Division of Nephrology has suggested that COVID-19-related kidney damage should follow tests to ensure kidney function returns to normal. Therefore, the growing burden of COVID-19 in the region is expected to increase the need for kidney test in North America.
According to the Canadian Organ Replacement Register Annual Statistics 2019, one in 10 Canadians had kidney disease, estimated at 4 million. The leading cause of kidney failure has been diabetes in the country.
A urine test is performed to check the presence of albumin in the urine. Albumin is a protein that can enter the urine when the kidneys are damaged. Kidney damage is caused by diseases such as diabetes, high blood pressure and heart disease. There is a significant burden of these diseases in the region, which leads to an increase in diagnostic tests for kidney function, and thus increases market growth.
The introduction of growing product and the growing advances in urine analysis in the region are boosting the market. For example, in March 2019, the United States Food and Drug Administration (FDA) approved a smartphone-based home urine test that allows patients with chronic illnesses, urinary tract infections, or high-risk pregnant women to monitor their health using a screening method. , Dip.io urine testing program, developed by Israel-based Healthy.io. Therefore, because of the above, the market learned is expected to grow in the North American region at the time of forecasting.
The Kidney Function Tests Market is fragmented in terms of competition, and it consists of several major players. In terms of market share, a few major players are currently dominating the market. Some companies currently dominating the market include F.Hoffmann-La Roche Ltd, ACON Laboratories Inc., 77 Elektronika Kft, Nova Biomedical, and Quest Diagnostics.
This product will be delivered within 2 business days.
Kidney function tests are simple procedures that often use blood or urine to help diagnose problems within the kidneys. COVID-19 has also affected patients' kidney function. According to a study "Association of Proteinuria and Hematuria with Acute Kidney Injury and Mortality in Hospitalized Patients with COVID-19" published in November 2020, more than 40% of admitted patients with COVID-19 showed symptoms of abnormal kidney function, such as albuminuria or hematuria. The market is projected to grow during the violence due to increased screening of patients with corona worldwide. Furthermore, according to a study published in medRXiv in April 2020, in adult patients, COVID-19 urinary incontinence was commonly found in patients with moderate to severe disease. In children, exposure to the urinary tract COVID-19 has been reported among those who suffer from a mild form of COVID-19. Urinary tract infections COVID-19 were detected from day 1 to day 52 after the onset of the disease.
Some of the factors driving the growth of the market include an increase in chronic kidney disease, an increase in awareness about diagnostic methods for kidney function, and technological advances in diagnostic equipment and tools.
According to a study "HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis" published in January 2021, the estimated number of people with diabetes worldwide, and 20 times higher than the number of people living with HIV / AIDS worldwide. Therefore, kidney disease is one of the most common diseases in the world, which is expected to boost market growth as this will increase the need for kidney function tests to control the disease.
In addition, diabetes and high blood pressure are considered major factors in the growing burden of chronic kidney disease worldwide. According to the International Diabetes Atlas tenth Edition 2021, 537 million adults (20-79 years) are living with diabetes, approximately1 in 10. This number is predicted to rise to 643 million by 2030 and 783 million by 2045. Over 3 in 4 adults with diabetes live in low- and middle-income countries.
Additionally, market players embrace a variety of strategies such as product launch, development, collaboration, acquisition, integration, and expansion to maximize market share. For example, in August 2020, RenalytixAI received approval from the Unitd States Food and Drug Administration (FDA) for its new KidneyIntelX test. AI-enabled clinical trials designed to identify and improve clinical management of patients with Type 2 diabetes with rapid progressive kidney disease. The emergence of highly technologically advanced products is expected to further market growth in the forecast period.
However, the high cost of diagnostic procedures and strict regulations are expected to hamper market growth in the near future.
Key Market Trends
The Dipstick Test Segment is Expected to Hold a Major Market Share in the Kidney Function Tests Market
Dipstick is a type of plastic stick that has a chemical line on it in the form of lines. Dipstick is dipped in urine, and when the color of the ribbon changes, it indicates the presence of abnormal substances such as protein, blood, redness, bacteria, and sugar. This helps to identify a range of kidney and urinary problems such as chronic kidney disease, bladder diseases, and kidney stones.
Report published by National Kidney Foundation Inc. in March 2020 stated that hospitalized people with COVID-19 were at higher risk of serious kidney injury (AKI), which could lead to serious illness and even death. A similar study found that patients with COVID-19, who were hospitalized between March 11 and April 26, 2020, were twice as likely to develop AKI compared to non-COVID patients who developed AKI simultaneously in 2019, which was calculated. 56.9% compared to 25.1%, respectively. In August 2021, ID Genomics (IDG), a Seattle-based company, has invented a dipstick-based, for simultaneous identification for large number of genetic variants of SARS-CoV2 and received a grant of USD 300,000 from National Institute of Health (NIH).
In addition, according to the above source, most patients with serious COVID-19 (AKI) complications are still working on the lower kidneys after recovery. According to the study "Using dipstick urinalysis to predict the development of kidney damage in patients with COVID-19" published in February 2022, the levels of proteinuria and hematuria in dipstick urine analysis can be used to predict AKI and renal replacement therapy (RRT ) in hospitalized patients. by COVID-19.Therefore, an increase in the incidence of kidney failure and chronic kidney failure due to COVID is expected to promote partial growth during the forecast period due to ease of diagnosis and availability.
Globally, rising government efforts to address and treat kidney disease are at the forefront of the dipstick test. In addition, the increase in the number of adults and the growing investment in the field of kidney function testing is driving partial growth. For example, in January 2020, Sweden's Elypta AB collected a USD 7.0 million fund for a urine cancer screening test. Additionally, in February 2019, Healthy.io raised USD 18 million for home urine testing in a Series B sponsorship led by Aleph, with the participation of Samsung Followers and individual investors. Therefore, because of the above factors, the segment may witness growth during the forecast period.
North America Dominates the Market and is Expected to Remain the Same in the Forecast Period
Some of the factors driving the growth of the market in the North American region include better health care infrastructure, an increase in urinary tract infections, and more widely available diagnostic tests.
The impact of coronavirus was significant in the region, especially in the North America. The Johns Hopkins Division of Nephrology has suggested that COVID-19-related kidney damage should follow tests to ensure kidney function returns to normal. Therefore, the growing burden of COVID-19 in the region is expected to increase the need for kidney test in North America.
According to the Canadian Organ Replacement Register Annual Statistics 2019, one in 10 Canadians had kidney disease, estimated at 4 million. The leading cause of kidney failure has been diabetes in the country.
A urine test is performed to check the presence of albumin in the urine. Albumin is a protein that can enter the urine when the kidneys are damaged. Kidney damage is caused by diseases such as diabetes, high blood pressure and heart disease. There is a significant burden of these diseases in the region, which leads to an increase in diagnostic tests for kidney function, and thus increases market growth.
The introduction of growing product and the growing advances in urine analysis in the region are boosting the market. For example, in March 2019, the United States Food and Drug Administration (FDA) approved a smartphone-based home urine test that allows patients with chronic illnesses, urinary tract infections, or high-risk pregnant women to monitor their health using a screening method. , Dip.io urine testing program, developed by Israel-based Healthy.io. Therefore, because of the above, the market learned is expected to grow in the North American region at the time of forecasting.
Competitive Landscape
The Kidney Function Tests Market is fragmented in terms of competition, and it consists of several major players. In terms of market share, a few major players are currently dominating the market. Some companies currently dominating the market include F.Hoffmann-La Roche Ltd, ACON Laboratories Inc., 77 Elektronika Kft, Nova Biomedical, and Quest Diagnostics.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD Million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- F.Hoffmann-La Roche Ltd
- URIT Medical Electronic Co. Ltd
- Arkray Inc.
- Abbott Laboratories
- Nova Biomedical
- Sysmex Corporation
- ACON Laboratories Inc.
- 77 Elektronika Kft
- Randox Laboratories
- Quest Diagnostics
- bioMérieux SA
- Laboratory Corporation of America Holdings
Methodology
LOADING...
